Table 2.
Medication use and disease characteristics of the patients with autoimmune Addison disease
| Type of GC | All, n = 57 | Female, n = 33 | Male, n = 24 | P (female vs male) |
|---|---|---|---|---|
| IR-HC (n) | 45 | 25 | 20 | – |
| GC dose (mg/m2/d)a (mean (SD)) | 13.3 (3.5) | 13.2 (3.5) | 13.4 (3.6) | .825 |
| Doses/d (mean (SD)) | 2.6 (0.7) | 2.6 (0.7) | 2.6 (0.7) | .849 |
| MR-HC (n) | 12 | 8 | 4 | – |
| GC dose (mg/m2/d)b (mean (SD)) | 12.5 (2.7) | 11.5 (2.3) | 14.5 (2.4) | .082 |
| Doses/d (mean (SD)) | 1.3 (0.7)c | 1.3 (0.5) | 1.5 (1.0) | .662 |
| Florinef, median dose in mg (range) | 0.1 (0.05-0.25) | 0.1 (0.05-0.25) | 0.1 (0.05-0.20) | .411 |
| Disease characteristics | ||||
| Age at AAD diagnosis, y (mean (SD)) Median Range |
22.9 (6.7) 23 8-34 |
23.3 (6.6) 23 10-34 |
22.5 (7.1) 21.5 8-34 |
.650 – – |
| AAD duration, y (mean (SD)) Median Range |
9.6 (4.9) 9.8 2.5-24.9 |
9.6 (4.0) 9.9 2.5-18 |
9.6 (6.0) 8.5 2.8-24.9 |
.999 – – |
| No. of adrenal crises (mean (SD)) Median Range |
3.2 (5.1) 1 0-25 |
3.9 (5.6) 1 0-25 |
2.3 (4.2) 1 0-20 |
.221 – – |
| Hypothyroidism | 43.9% | 48.5% | 37.5% | .579 |
P values indicate comparisons between male and female patients; t tests were used except for the occurrence of hypothyroidism, for which a chi-square test was used. From those on IR-HC replacement therapy, 2 patients had only 1 dose per day, 18 had 2 doses per day, 22 had 3 doses per day, and 3 patients had 4 doses per day.
Abbreviations: AAD, autoimmune Addison disease; GC, glucocorticoid; IR-HC, immediate-release hydrocortisone; MR-HC, modified-release hydrocortisone.
a Total IR-HC dose per day in mg per m2 of body surface (total mg/sqrt (cm × kg/3600)).
b Total IR-HC equivalence dose per day in mg per m2 of body surface (total mg/sqrt (cm × kg/3600)).
c Some participants on MR-HC take additional IR-HC doses on demand.